Chinese Fibromyalgia Market is expected to grow at a CAGR of 18.7% during the forecast period PREPARED BY Market Research Future (Part of Wantstats Research & Media Pvt. Ltd.) SAMPLE FOR MORE INFO

Market Highlights: Fibromyalgia syndrome co-exists with other painful conditions, such as migraine and other types of headaches, temporomandibular joint disorders, irritable bowel syndrome (IBS), and interstitial cystitis. The treatment of fibromyalgia includes both targeted and symptomatic approach. Till date, there are only three FDA approved drugs for the fibromyalgia treatment, i.e., Lyrica (PFIZER), Cymbalta (Eli Lilly and Company), and Savella (Allergan plc). However, there are few other drugs prescribed by physicians to control the symptoms of fibromyalgia such as pain relievers, muscle relaxants, and traditional Chinese medicine. Growing geriatric population, increasing cases of rheumatic diseases, growing awareness among the population, and rising incidences of traumatic stress and road accidents are the key factors driving the Chinese fibromyalgia market. According to a study published in the Arthritis Care & Research journal in 2017, fibromyalgia and related symptoms worsen the functional status of individuals with rheumatoid arthritis. Around 15%-30% of patients with rheumatic disorders have co-morbid fibromyalgia syndrome. Request For Sample Report: Chinese Fibromyalgia Market

Chinese Fibromyalgia Market Regional Analysis South Central China accounted for the major share of the market owing to the rising prevalence of fibromyalgia in this region. Rising cases of chronic rheumatic diseases are also capable of fuelling the fibromyalgia market in China. Prevalence of rheumatoid arthritis is around 0.35%, with the significantly higher rate in Northern China as compared to the Southern part. The rising healthcare expenditure is also propelling the growth of the market. In China, the total expenditure on health per capita in 2014 was USD 731, as per the World Health Organization (WHO) in The health expenditure in China grew at a rate of 11.6% per year, suggested by a study published in BMC Health Services Research journal in This rate is much faster than the growth of the country’s economy, i.e., 9.9% per year. Get

Chinese Fibromyalgia Market Segmentation The Chinese fibromyalgia market is segmented on the basis of diagnosis, treatment, and end-user. On the basis of the diagnosis, the market is classified into laboratory evaluation and presence of central sensitization. On the basis of the treatment, the market is segmented into targeted treatment and symptomatic treatment. On the basis of the end-users, the market is segmented into hospitals, clinics, diagnostic centers, and others.

ABOUT US MARKET RESEARCH FUTURE At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members. For more information kindly visit or contact us at Copyright © 2018 Market Research Future All Rights Reserved. This document contains highly confidential information and is the sole property of Market Research Future. No part of it may be circulated, copied, quoted, or otherwise reproduced without the written approval of Market Research Future.

MARKET RESEARCH FUTURE THANK YOU Ph: (US) Ph: (UK)